Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A

Gouri Shankar Pandey, Chen Yanover, Lisa M. Miller-Jenkins, Susan Garfield, Shelley A. Cole, Joanne E. Curran, Eric K. Moses, Natalia Rydz, Vijaya Simhadri, Chava Kimchi-Sarfaty, David Lillicrap, Kevin R. Viel, Teresa M. Przytycka, Glenn F. Pierce, Tom E. Howard, Zuben E. Sauna, Jeanne Lusher, Meera Chitlur, Afshin Ameri, Kavita NatarajanRathi V. Iyer, Alexis A. Thompson, Raymond G. Watts, Christine L. Kempton, Craig Kessler, John C. Barrett, Erica J. Martin, Nigel Key, Rebecca Kruse-Jarres, Cindy Lessinger, Kathleen P. Pratt, Neil Josephson, Kevin McRedmond, Janice Withycombe, Christopher Walsh, Dana Matthews, Johnny Mahlangu, Amanda Krause, Rosemary Schwyzer, Rajendra Thejpal, Nadine Rapiti, Yasmin Goga, Marius Coetzee, David Stones, Kenneth Mann, Saulius Butenas, Laura Almasy, John Blangero, Mel Carless, Rajalingam Raja, Elaine Reed

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Fingerprint

Dive into the research topics of 'Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds